Wearable Devices for Assessing Exercise Targeting Bone Health in Post-Menopausal Women with Low Bone Mineral Density

Not Applicable

Completed

• Conditions: osteoporosis; osteopenia; Musculoskeletal - Osteoporosis; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12618000101280
• Lead Sponsor: Professor Peter Ebeling

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-01-23
• Study Completion: 2019-07-31
• Last Update Posted: 12 July 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

Experienced menopause
-Low BMD (<-1.0 T-Score at hip or lumbar spine). Confirmed by DXA scan performed by investigators or self-reported diagnosis in past two years (confirmed by GP)
-Community-dwelling
-GP approval to participate in study
-BMI <30kg/m2
-<150 minutes of self-reported moderate-vigorous physical activity per week

Exclusion Criteria

-Self-reported knee or hip osteoarthritis
-Recent surgery (<6 months)
-Recently undertaken structured exercise regime. Eg; running program/resistance training
-Self-reported inability to walk 400 metres, non-stop and unassisted.
-Non-English speaking
-Regular corticosteroid use (within 3 months)
-Progressive neurological disorder. Eg; Parkinson’s, Alzheimer’s, Multiple Sclerosis etc.
-Lung disease requiring supplemental oxygen
-Any other severe disorder where life expectancy is <12 months
-Myocardial infarction or severe cardiovascular disease
-Any other condition that in the opinion of the investigators may deem the performance of study unsafe

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
bone mineral density will be assessed by dual energy x-ray absorptiometry and quantitative ultrasonography. <br> [week 16];bone microarchitecture will be assessed by High-resolution peripheral quantitative computed tomograhy and regular peripheral quantitative computed tomography[week 16]

Secondary Outcome Measures

Name	Time	Method
lean skeletal muscle mass is assessed by dual energy x-ray absorptiometry.[week 16];Bone turnover markers, c-terminal telopeptide (B-CTX) and procollagen type 1 propetide (P1NP). Assessed by blood biochemical analysis[weeks 1 and 16];Short physical performance battery.[Weeks 1,5,9 and 16]